An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

Phase 2

Completed

• Conditions: Renal Cell Carcinoma
• Interventions: Biological: Opdivo; Biological: Yervoy

• Registration Number: NCT03029780
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of this study is to evaluate safety and efficacy of different administration regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-01-20
• Study First Submitted QC: 2017-01-20
• Study First Posted: 2017-01-24
• Study Start: 2017-02-16
• Primary Completion: 2017-11-27
• Results First Submitted: 2018-11-27
• Results First Submitted QC: 2018-11-27
• Results First Posted: 2018-12-19
• Study Completion: 2021-06-15
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-01
• Last Update Posted: 2022-06-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

• Advanced Renal Cell Carcinoma
• Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work
• Must have at least 1 lesion with measurable disease

Read More

Exclusion Criteria

• Subjects with active central nervous system metastases
• Subjects who received prior therapy with checkpoint inhibitor
• Subjects with active, known or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Co-Administration	Opdivo	Nivolumab and Ipilimumab Co-Administration
Sequential Administration	Opdivo	Nivolumab and Ipilimumab Sequential Administration
Co-Administration	Yervoy	Nivolumab and Ipilimumab Co-Administration
Sequential Administration	Yervoy	Nivolumab and Ipilimumab Sequential Administration

Primary Outcome Measures

Name	Time	Method
The Percentage of Participant With Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Within 2 Days After Any Dose in the Combination Period	From randomization to 2 days following any dose in the combination period (assessed up to November 24th, 2017, approximately 9 months)	The percentage of participants who experienced at least 1 adverse event in the MedDRA Anaphylactic Reaction broad scope SMQ with onset on the day of or within 2 days after any study therapy infusion during the combination period (Part 1).

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival (PFS)	From randomization to the first date of documented progression or death due to any cause (up to approximately 52 months)	The time between the date of randomization and the first date of documented progression, or death due to any cause, whichever occurs first (per investigator). Participants who die without progression will be considered to have progressed on the date of their death. Participants who did not progress or die are censored on the date of their last evaluable tumor assessment. Participants with no on study tumor assessments and who did not die will be censored on their date of randomization. Participants who started anti-cancer therapy without a prior reported progression will be censored on the date of their last evaluable tumor assessment prior to the first subsequent anti-cancer therapy. Progression is defined as at least a 20% increase in the sum of diameters of target lesions. The sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)
The Percentage of Participant With Adverse Events in the Narrow Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Occurring Within 2 Days After Any Dose in the Combination Period	From randomization to 2 days following any dose in the combination period (assessed up to November 24th, 2017, approximately 9 months)	The percentage of participants who experienced at least 1 adverse event in the MedDRA Anaphylactic Reaction narrow scope SMQ with onset on the day of or within 2 days after any study therapy infusion during the combination period (Part 1).
The Percentage of Participants With All Causality Grade 3-5 Adverse Events	From first dose to 30 days after last dose of study therapy (up to approximately 48 months)	The percentage of participants who experienced at least 1 adverse event of Grade 3 or higher with onset on or after the first dose of study treatment and within 30 days of the last dose of study treatment. Evaluated using the NCI CTCAE version 4.0 criteria
Objective Response Rate (ORR)	From randomization to the date of objectively documented progression or the date of first subsequent anti-cancer (up to approximately 52 months)	The percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). The BOR is defined as the best response designation, as determined by the investigator, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of first subsequent anti-cancer therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR assessment. Complete Response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10mm. Partial Response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Geometric Mean End of Infusion (EOI) Concentrations of Nivolumab and Ipilimumab	EOI on day 1 of cycle 1, 2, and 4	Serum concentration-time data of nivolumab and ipilimumab administered as a fixed ratio combination to that of sequentially administered nivolumab and ipilimumab is summarized at the end of infusion (EOI). 1 Cycle = 3 weeks
The Percentage of Participants With Drug Related Grade 3-5 Adverse Events	From first dose to 30 days after last dose of study therapy (up to approximately 48 months)	The percentage of participants who experienced at least 1 adverse event of Grade 3 or higher, judged to be related to study treatment by the investigator, with onset on or after the first dose of study treatment and within 30 days of the last dose of study treatment. Evaluated using Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria.
Geometric Mean Trough Concentrations of Nivolumab and Ipilimumab	pre-dose on day 1 of cycle 2 and 4	Serum concentration-time data of nivolumab and ipilimumab administered as a fixed ratio combination to that of sequentially administered nivolumab and ipilimumab is summarized prior to the next dose (predose). 1 Cycle = 3 weeks

Trial Locations

Locations (6)

Centro Internacional de Estudios Clinicos; 🇨🇱 Recoleta, Santiago De Chile, Chile

Fundacion Arturo Lopez Perez; 🇨🇱 Santiago, Metropolitana, Chile

Levine Cancer Institute; 🇺🇸 Charlotte, North Carolina, United States

Cancer Specialists of North FL; 🇺🇸 Jacksonville, Florida, United States

University Of Iowa Hospitals And Clinics; 🇺🇸 Iowa City, Iowa, United States

Local Institution; 🇦🇺 Malvern, Victoria, Australia